WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2013148260) METHODS FOR MODULATING TAU EXPRESSION FOR REDUCING SEIZURE AND MODIFYING A NEURODEGENERATIVE SYNDROME
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2013/148260    International Application No.:    PCT/US2013/031500
Publication Date: 03.10.2013 International Filing Date: 14.03.2013
IPC:
C12N 15/11 (2006.01), C07H 21/00 (2006.01)
Applicants: WASHINGTON UNIVERSITY [US/US]; One Brookings Drive St. Louis, Missouri 63130 (US).
ISIS PHARMACEUTICALS, INC. [US/US]; 2855 Gazelle Court Carlsbad, California 92010 (US).
MILLER, Timothy M. [US/US]; (US) (US only).
DEVOS, Sarah [US/US]; (US) (US only).
BENNETT, C. Frank [US/US]; (US) (US only).
RIGO, Frank [US/US]; (US) (US only)
Inventors: MILLER, Timothy M.; (US).
DEVOS, Sarah; (US).
BENNETT, C. Frank; (US).
RIGO, Frank; (US)
Agent: RILEY-VARGAS, Rebecca; Polsinelli Shughart PC Mark Twain Plaza III 105 West Vandalia, Suite 400 Edwardsville, IL 62025 (US)
Priority Data:
61/618,435 30.03.2012 US
61/660,676 15.06.2012 US
61/719,149 26.10.2012 US
Title (EN) METHODS FOR MODULATING TAU EXPRESSION FOR REDUCING SEIZURE AND MODIFYING A NEURODEGENERATIVE SYNDROME
(FR) PROCÉDÉS DE MODULATION DE L'EXPRESSION DE TAU POUR RÉDUIRE L'AVC ET MODIFIER UN SYMPTÔME NEURODÉGÉNÉRATIF
Abstract: front page image
(EN)Disclosed herein are methods for reducing expression of Tau mRNA and protein in an animal with Tau antisense compounds. Also disclosed are methods for modulating splicing of Tau mRNA in an animal with Tau antisense compounds. Such methods are useful to treat, prevent, or ameliorate neurodegenerative diseases in an individual in need thereof. Examples of neurodegenerative diseases that can be treated, prevented, and ameliorated with the administration Tau antisense oligonucleotides include Alzheimer's Disease, Fronto-temporal Dementia (FTD), FTDP-17, Progressive Supranuclear Palsy, Chronic Traumatic Encephalopathy, Epilepsy, and Dravet's Syndrome.
(FR)Cette invention concerne des procédés permettant de réduire l'expression de l'ARNm de Tau et de la protéine Tau chez un animal à l'aide de composés antisens Tau. Cette invention concerne également des procédés de modulation de l'épissage de l'ARNm de Tau chez un animal à l'aide de composés antisens Tau. Ces procédés sont utiles pour traiter, prévenir, ou améliorer les maladies neurodégénératives chez un individu en ayant besoin. A titre d'exemples de maladies neurodégénératives qui peuvent être traitées, prévenues, et améliorées par l'administration d'oligonucléotides antisens Tau, il y a la maladie d'Alzheimer, la démence fronto-temporale (FTD), FTDP-17, la paralysie supranucléaire progressive, l'encéphalopathie traumatique chronique, l'épilepsie, et le syndrome de Dravet.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)